• English
  • Français
  • Русский

Metronidazole BP 2014

Antiprotozoal and Anaerobic Bactericide
Each film coated tablet contains 250 mg metronidazole.
Carton box contains 1, 2, 3 strips, each of 10 tablets.
Amoebiasis • Adults: 1.5 g daily in 3 divided doses. In hepatic amoebiasis, at the abscess stage, the abscess must be evacuated concomitantly with metronidazole treatment. The duration of the treatment is 7 consecutive days. Giardiasis • Adults: 0.750 to 1 g daily for 5 consecutive days. • Children: (10 to 15 years): 500 mg/day Lambliasis (for 5 consecutive days) • Adults: 750 mg to 1 g per day • Children: (from 10 to 15 years): 500 mg daily Trichomoniasis • In females (urethritis and vaginitis due to Trichomonas): Single dose of 2 g or 500 mg by oral route in 2 divided doses for 10 days. Whether or not the partner presents clinical signs of infection with Trichomonas vaginalis, he must be treated concurrently, even in the absence of positive laboratory tests. • In males (urethritis due to Trichomoniasis): 2 g in a single dose, or 500 mg by oral route in 2 divided doses for 10 days. • Non-specific vaginitis: 500 mg, twice daily for 7 days. The partner must be treated simultaneously. • Anaerobic infections (as first line or substitute treatment): Adults: 1 to 1.5 g/day Surgical Chemoprophylaxis The studies published in literature do not make it possible to define the ideal protocol for surgical chemoprophylaxis. Metronidazole must be combined with a product active against enterobacteria. • Adults: one 500 mg dose every 8 hours. Beginning the treatment approximately 48 hours before surgery, appears to be effective. The last dose must be administered at the latest 12 hours before surgery, The goal of chemoprophylaxis is to reduce the bacterial inoculum in the gastrointestinal tract at the time of surgery; it is therefore useless to continue the antibiotic in the post-operative period, at least by the oral route.
Indications are based on the anti-parasitic and antibacterial activity of metronidazole and on its pharmacokinetic characteristics. They are intended for the treatment of infections due to the pathogens susceptible to metronidazole: • Amoebiasis • Giardiasis • Lambliasis • Urogenital trichomoniasis • Non-specific vaginitis • Curative treatment of medico-surgical infections due to susceptible anaerobic pathogens • Prophyalxis against infections caused by susceptible anaerobic pathogens in high risk surgical contexts • Folllowing prophylactic or curative treatment by injection, of infections due to susceptible anaerobes.
Therapeutic Lines: 
Dosage Form: 

Medical Union Pharmaceuticals newsletter

Subscribe with your e-mail address to stay up-to-date. We will send you all new MUP news, product launches, Pharmacovigilance cases and our activity to be up-to-date

Go to top